SLC5A2 and cardiovascular disorder: Patients of different ages, races, cardiovascular risk groups, with adequate or inadequate carbohydrate metabolism, and taking various blood sugar-lowering medications (SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of cardiovascular diseases) participated in the included studies.